Tygh Capital Management’s Trinity Biotech TRIB Stock Holding History

Tygh Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-35,100	Closed	-$2.01M	–	99
2015 Q3	$2.01M	Sell	35,100 -11,176	-24%	-$899K	0.48%	75
2015 Q2	$4.18M	Buy	46,276 +3,184	+7%	+$276K	0.75%	69
2015 Q1	$4.15M	Buy	43,092 +22,966	+114%	+$2.12M	0.76%	68
2014 Q4	$1.76M	Buy	20,126 +5,009	+33%	+$432K	0.34%	89
2014 Q3	$1.38M	Sell	15,117 -12,267	-45%	-$1.33M	0.3%	94
2014 Q2	$3.15M	Buy	+27,384	New	+$3.25M	0.67%	76

Other funds holding TRIB

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

AAM

ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Tygh Capital Management's TRIB Position: Q4 2015 in Review

Tygh Capital Management sold out of Trinity Biotech (TRIB) in Q4 2015, closing a stake of 35,100 shares — an estimated $2.01M sold.

Tygh Capital Management first reported a position in TRIB in Q2 2014 and held it in 6 quarters. The position peaked at $4.18M in Q2 2015. 82 funds tracked by Wall St. Rank hold TRIB as of Q4 2015.

Tygh Capital Management reported no remaining Trinity Biotech position as of Q4 2015 after selling out during the quarter.
Tygh Capital Management sold 35,100 Trinity Biotech shares in Q4 2015, an estimated $2.01M.
Tygh Capital Management first reported a position in Trinity Biotech in Q2 2014 and held it in 6 quarters.
Tygh Capital Management's Trinity Biotech position peaked at $4.18M in Q2 2015.
82 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2015.

Based on Tygh Capital Management's 13F filing for Q4 2015, filed 2 Feb 2016.